Purchase this article with an account.
A. A. Alezzandrini, M. Charles, M. J. Saravia, G. Iribarren, M. Zas, A. Bastien, D. Bar, E. Rosendi, M. Garcia, M. Della Savia; Endophtalmitis Following Intravitreal Injection of Anti VEGF Therapy : A Multicentric Study. Invest. Ophthalmol. Vis. Sci. 2010;51(13):2807.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To identify the incidence of endophthalmitis after intravitreal anti VEGF injections (Bevacizumab) and report the clinical outcomes in our practice.
Retrospective multicentric analysis of 6040 intravitreal anti VEGF injections (Bevacizumab - Avastin) applied from July 2005 through July 2009 in several Argentinian Ophthalmologic Centres. 5418 (89,7%) of the applications were performed in operating rooms under strict antiseptic conditions and 622 (10,3%) of the injections were made in a physician's office, also following the same strict measures.
Endophthalmitis developed in 2 of the 6040 eyes (0.03%) after anti VEGF pars plana injections.In every case, signs and symptoms of endophthalmitis appeared within 2 days from the injection, and both patients had received the anti VEGF injection in operating rooms. The microorganisms recovered were staphylococcus aureus and coagulase-negative staphylococcus.
AntiVEGF applied via pars plana, whether made in operating rooms or in physicians office is a safe procedure for treating several retinal diseases.
This PDF is available to Subscribers Only